Braidwell LP Acquires 61,512 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Braidwell LP boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 57.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 168,691 shares of the company’s stock after acquiring an additional 61,512 shares during the quarter. Braidwell LP owned 0.59% of Krystal Biotech worth $30,707,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Krystal Biotech by 3.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock valued at $840,000 after acquiring an additional 153 shares during the period. Blueshift Asset Management LLC bought a new stake in Krystal Biotech during the third quarter worth about $332,000. BNP Paribas Financial Markets grew its stake in Krystal Biotech by 346.8% during the third quarter. BNP Paribas Financial Markets now owns 10,433 shares of the company’s stock worth $1,899,000 after buying an additional 8,098 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new stake in Krystal Biotech during the third quarter worth about $417,000. Finally, Summit Trail Advisors LLC bought a new stake in Krystal Biotech during the third quarter worth about $1,893,000. Institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Tuesday, November 5th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Stifel Nicolaus increased their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Chardan Capital increased their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Finally, Citigroup increased their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and a consensus target price of $202.29.

Krystal Biotech Stock Performance

KRYS opened at $196.91 on Friday. The firm’s fifty day moving average is $180.23 and its two-hundred day moving average is $183.28. The firm has a market cap of $5.66 billion, a PE ratio of 111.25 and a beta of 0.82. Krystal Biotech, Inc. has a twelve month low of $99.00 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same period last year, the business posted ($0.67) earnings per share. The business’s revenue for the quarter was up 879.9% compared to the same quarter last year. Equities analysts forecast that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).